Chiasma (Chiasma) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2021)

View and export this data going back to 2015. Start your Free Trial

What is Chiasma LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Chiasma's long-term debt to total assests ratio for the quarter that ended in Mar. 2021 was 0.00.

Chiasma's long-term debt to total assets ratio stayed the same from Mar. 2020 (0.00) to Mar. 2021 (0.00).

Chiasma LT-Debt-to-Total-Asset Historical Data

The historical data trend for Chiasma's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiasma LT-Debt-to-Total-Asset Chart

Chiasma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Chiasma Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Chiasma LT-Debt-to-Total-Asset Calculation

Chiasma's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2020 is calculated as

LT Debt to Total Assets (A: Dec. 2020 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2020 )	/	Total Assets (A: Dec. 2020 )
	=	0	/	176.338
	=	0.00

Chiasma's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2021 is calculated as

LT Debt to Total Assets (Q: Mar. 2021 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2021 )	/	Total Assets (Q: Mar. 2021 )
	=	0	/	159.535
	=	0.00

Chiasma (NAS:CHMA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Chiasma LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Chiasma's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Chiasma (Chiasma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiasma Inc (NAS:CHMA) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

140 Kendrick Street, Building C East, Needham, MA, USA, 02494

Website

https://www.chiasmapharma.com

Chiasma Inc is a commercial-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for rare and serious chronic disease. The US Food and Drug Administration, or the FDA, approved MYCAPSSA for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog, or SSA, approved by the FDA and the first product approved by the FDA utilizing TPE technology. The company is focused on the commercialization of MYCAPSSA for the treatment of patients with acromegaly in the United States and developing and seeking regulatory approval of MYCAPSSA in the European Union.

Executives

Roni Mamluk	director	CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459
David M Stack	director	THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Raj Kannan	director, officer: Chief Executive Officer	C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
John F Thero	director	C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Bard Geesaman	director	C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142
Todd Foley	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
John A Scarlett	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Scott Minick	director	C/O BIND THERAPEUTICS, INC. 325 VASSAR ST CAMBRIDGE MA 02139
Anand Varadan	officer: EVP, Chief Commerical Officer	C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459
Lee Giguere	officer: General Counsel	C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451
William Ludlam	officer: See Remarks	C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451
Drew Enamait	officer: VP, Fin & Admin, PAO	C/O CHIASMA, INC. 275 WYMAN STREET, SUITE 250 WALTHAM MA 02451
Mark J. Fitzpatrick	officer: President	101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ansbert Gadicke	director	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116